153304-75-7

Upstream product

• 110073-67-1 methyl 4-amino-3-ethenylbenzoate 
• 578-54-1 ortho-ethylaniline 
• 619-45-4 4-methoxycarbonyl aniline 
• 19718-49-1 4-amino-3-iodobenzoic acid methyl ester 
• 97-94-9 triethyl borane 
• 106896-49-5 methyl 4-amino-3-bromobenzoate 
• 67-56-1 methanol 
• 51688-75-6 4-amino-3-ethylbenzoic acid 

Downstream Products

• 1449664-55-4 methyl 3-ethyl-4-(1-methyl-1H-imidazo[4,5-c]pyridin-6-ylamino)benzoate 
• 1449664-56-5 (3-ethyl-4-(methyl(1-methyl-1H-imidazo[4,5-c]pyridin-6-yl)amino)phenyl)methanol 
• 1449664-57-6 3-ethyl-N-methyl-4-(methyl(1-methyl-1H-imidazo[4,5-c]pyridin-6-yl)amino)benzamide 
• 1449664-58-7 N-(2-cyanoethyl)-3-ethyl-4-(methyl(1-methyl-1H-imidazo[4,5-c]pyridin-6-yl)amino)benzamide 
• 1449667-53-1 (3-ethyl-4-(methyl(1-methyl-1H-imidazo[4,5-c]pyridin-6-yl)amino)phenyl)(4-methylpiperazin-1-yl)methanone 
• 1449669-07-1 3-ethyl-4-(methyl(1-methyl-1H-imidazo[4,5-c]pyridin-6-yl)amino)benzaldehyde 
• 1449664-61-2 1-(3-ethyl-4-(methyl(1-methyl-1H-imidazo[4,5-c]pyridin-6-yl)amino)phenyl)ethanol 
• 1449664-62-3 2-(3-ethyl-4-(methyl(1-methyl-1H-imidazo[4,5-c]pyridin-6-yl)amino)phenyl)propan-2-ol 
• 1449664-63-4 N-(2-ethyl-4-(methoxymethyl)phenyl)-N,1-dimethyl-1H-imidazo[4,5-c]pyridin-6-amine 
• 1449667-59-7 N-(4-((1H-imidazol-1-yl)methyl)-2-ethylphenyl)-N,1-dimethyl-1H-imidazo[4,5-c]pyridin-6-amine 
• 1449667-60-0 (3-ethyl-4-(methyl(1-methyl-1H-imidazo[4,5-c]pyridin-6-yl)amino)phenyl)(4-methoxypiperidin-1-yl)methanone 
• 1449670-50-1 3-ethyl-4-(methyl(1-methyl-1H-imidazo[4,5-c]pyridin-6-yl)amino)benzoic acid 
• 1449667-77-9 N-(2-ethyl-4-((methylamino)methyl)phenyl)-N,1-dimethyl-1H-imidazo[4,5-c]pyridin-6-amine 
• 1449664-71-4 N-(2-ethyl-4-((4-(methylsulfonyl)piperazin-1-yl)methyl)phenyl)-N,1-dimethyl-1H-imidazo[4,5-c]pyridin-6-amine 

Relevant academic research and scientific papers

Bioinspired Synthesis of Pinoxaden Metabolites Using a Site-Selective C-H Oxidation Strategy

A bioinspired synthesis of Pinoxaden metabolites 2-5 is described herein. A site-selective C-H oxidation strategy validated by density functional theory (DFT) calculations was devised for preparing metabolites 2-4. Oxidation of the benzylic C-H bond in tertiary alcohol 7 using K2S2O8 and catalytic AgNO3 formed the desired metabolite 2 that enabled access to metabolites 3 and 4 in a single step. Unlike most metal/persulfate-catalyzed transformations reported for the C-C and C-O bond formation reactions wherein the metal acts as a catalyst, we propose that Ag(I)/K2S2O8 plays the role of an initiator in the oxidation of intermediate 7 to 2. Metabolite 2 was subjected to a ruthenium tetroxide-mediated C-H oxidation to form metabolites 3 and 4 as a mixture that were purified to isolate pure standards of these metabolites. Metabolite 5 was synthesized from readily available advanced intermediate 9 via a House-Meinwald-type rearrangement in one step using a base.

NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS

The present invention discloses compounds according to Formula (I), wherein R1, R3, R4, R5, L1, and Cy are as defined herein. The present invention also provides compounds, methods for the production of said compounds of the invention, pharmaceutical compositions comprising the same and their use in allergic or inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 and/or interferons. The present invention also methods for the prevention and/or treatment of the aforementioned diseases by administering a compound of the invention.

IMIDAZO [4, 5 -C] PYRIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES

Wherein R1, L1, R3, R4, Cy, L2 and R5 are as defined herein. Novel imidazolopyridines according to Formula I, able to inhibit JAK are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic or inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.

2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS

The present invention relates to novel oxadiazole derivatives of formula (1) having pharmacological activity, processes for their preparation, compositions containing them and their use in the treatment of neurological, psychiatric disorders and gastrointestinal disorders through modulation of the nicotinic α7 receptor formula (I).